Dr. Karl Butterworth of Queen's University Belfast recently shared about his experience using SARRP for research as part of a SARRP panel. In this clip, you can hear the highlights of their biology research program, including future opportunities....
https://youtu.be/pugRTE0UKwU
https://youtu.be/RdLPMTHnGgQ
Recently, Dr. Steven Davis shared his experience of using RADiant in Dermatology Times. See his piece below. Steven A Davis, M.D., is a board-certified dermatologist and Medical Director of the Dermatology & Laser Center of San Antonio.
Over his career, Dr. Steven Davis, medical director of The Dermatology & Laser Center of San Antonio, has performed more than 25,000 skin cancer operations. While surgery is still the primary treatment, it's not always the best option for the patient, especially...
Non-melanoma skin cancers (NMSC) are the most commonly diagnosed cancers in the world. Despite their relatively low malignant potential and mortality rate, NMSC are associated with a high morbidity and substantial treatment cost, and they significantly affect patient...
The Xstrahl 100 is perfectly suited for the treatment of non-melanoma skin cancers, and with Australia recording skin cancer rates of 2 in every 3 adults, the need for an effective and versatile treatment method is essential. With the aim to offer non-melanoma skin...
Recently, the Radiobiology Research Group from the Centre for Cancer Research and Cell Biology at Queen’s University Belfast published a series of articles using SARRP to explore different translationally focused experimental approaches. The group, led by Prof Kevin Prise and Dr Karl Butterworth, have published three back to back papers within three months which reflect the interests of the research program in nanoparticle theranostics, bystander signaling and novel combination therapy.